

David W Holt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10453396/david-w-holt-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

3,859
citations

27
h-index

62
g-index

107
ext. papers

4,164
ext. citations

3.5
avg, IF

4.73
L-index

#	Paper	IF	Citations
106	Discussion: can upper extremity (deltoid) near infrared spectroscopy be used to assess cerebral tissue bed saturation on femorally cannulated veno-arterial extracorporeal membrane oxygenation patients?. <i>Perfusion (United Kingdom)</i> , 2021 , 36, 190-199	1.9	0
105	Quantification of mycophenolic acid in human plasma by liquid chromatography with time-of-flight mass spectrometry for therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2021 , 35, e5011	1.7	
104	Alternative Input for Perfusion Management Devices: Voice Recognition for Data Input and the Effects on Charting and Perioperative Calculation Use.. <i>Journal of Extra-Corporeal Technology</i> , 2021 , 53, 286-292	0.4	
103	Perfusion Recruitment Strategies Using Choice-Based Conjoint Analysis. <i>Journal of Extra-Corporeal Technology</i> , 2020 , 52, 218-226	0.4	
102	Comparison of three infant venous reservoirs with vacuum-assisted venous drainage during varying levels of cardiomy suction. <i>Perfusion (United Kingdom)</i> , 2020 , 35, 26-31	1.9	2
101	Improving Decreased Heater-Cooler Efficiency as a Result of Heater-Cooler Infection Control Strategy. <i>Journal of Extra-Corporeal Technology</i> , 2019 , 51, 73-77	0.4	
100	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. <i>Lancet, The</i> , 2018 , 391, 2411-140		8
99	Colloid Oncotic Pressure, Monitoring its Effects in Cardiac Surgery. <i>Journal of Extra-Corporeal Technology</i> , 2017 , 49, 249-256	0.4	
98	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 143-69	3.2	71
97	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 170-89	3.2	65
96	Substandard drugs: a potential crisis for public health. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 218-43	3.8	115
95	Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. <i>Clinical Chemistry</i> , 2013 , 59, 1630-7	5.5	35
94	The need for standardization of tacrolimus assays. <i>Clinical Chemistry</i> , 2011 , 57, 1739-47	5.5	48
93	Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 341-58	6.9	226
92	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 628-34	4.3	18
91	Case series of individuals with analytically confirmed acute mephedrone toxicity. <i>Clinical Toxicology</i> , 2010 , 48, 924-7	2.9	174
90	Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. <i>Journal of Medical Toxicology</i> , 2010 , 6, 327-30	2.6	161

89	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 139-52	3.2	347
88	Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. <i>Pharmacogenomics</i> , 2008 , 9, 585-96	2.6	19
87	A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. <i>Transplantation</i> , 2008 , 85, 163-5	1.8	40
86	First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. <i>European Journal of Emergency Medicine</i> , 2008 , 15, 354-6	2.3	21
85	Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. <i>Transplantation</i> , 2008 , 86, 1043-51	1.8	209
84	Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). <i>Journal of Medical Toxicology</i> , 2008 , 4, 167-9	2.6	27
83	Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). <i>Journal of Medical Toxicology</i> , 2008 , 4, 254-7	2.6	51
82	Detection of the pharmaceutical agent glaucine as a recreational drug. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 553-4	2.8	19
81	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2045-58	4	21
80	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. <i>Clinical Transplantation</i> , 2007 , 21, 252-7	3.8	28
79	Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. <i>Transplantation</i> , 2006 , 82, 705-8	1.8	46
78	An herbal remedy for impotence: more than was bargained for. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1379-81	2.9	4
77	Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. <i>Transplantation</i> , 2006 , 82, 1413-8	1.8	43
76	Therapeutic drug monitoring of mycophenolate mofetil in transplantation. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 145-54	3.2	275
75	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2593-605	4	6
74	Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. <i>Transplantation</i> , 2005 , 79, 499-502	1.8	156
73	CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay. <i>Clinical Chemistry</i> , 2005 , 51, 2214-5	5.5	10
72	Genotyping cytochrome P450 3A5 using the Light Cycler. <i>Annals of Clinical Biochemistry</i> , 2005 , 42, 376-81.2	1.2	17

71	The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. <i>American Journal of Transplantation</i> , 2004 , 4, 914-9	8.7	211
70	Monitoring immunosuppressive drugs. <i>Handbook of Analytical Separations</i> , 2004 , 273-296	0.7	1
69	Monitoring immunosuppressive drugs: has it a future?. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 244-7	3.2	6
68	Pharmacogenomics of immunosuppressive drug metabolism. <i>Current Opinion in Nephrology and Hypertension</i> , 2003 , 12, 607-13	3.5	22
67	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. <i>Molecular Diagnosis and Therapy</i> , 2003 , 3, 291-301		26
66	Bone turnover markers in clinical practice 2002 , 99-114		
65	The immunogenetics of metabolic liver disease 2002 , 177-189		
64	Biomarkers in gastrointestinal disease 2002 , 265-271		
63	Chronic allograft damage index as a surrogate marker for chronic allograft rejection 2002 , 433-441		2
62	Traumatic brain injury: assessment by biochemical serum markers 2002 , 398-405		0
61	The use of biomarkers for monitoring the response to immunosuppressive drug therapy 2002 , 451-460		
60	Markers of malabsorption: coeliac disease 2002 , 281-288		
59	Determinants of responses to viruses and self in liver disease 2002 , 244-255		
58	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. <i>Transplantation</i> , 2002 , 74, 1486-9	1.8	251
57	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 59-67	3.2	70
56	Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2002 , 11, 657-63	3.5	42
55	Monitoring mycophenolic acid. <i>Annals of Clinical Biochemistry</i> , 2002 , 39, 173-83	2.2	49
54	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover 2002 , 140-158		

53 Prognosis and management of patients with acute liver failure **2002**, 199-210

52 Genomics and biomarkers in toxicology **2002**, 291-298

1

51 Evidence-based medicine: evaluation of biomarkers **2002**, 3-15

1

50 Statistical approaches to rational biomarker selection **2002**, 24-31

1

49 Biochemical markers of bone resorption **2002**, 122-132

48 Biomarkers of hepatic disease **2002**, 167-176

1

47 Biomarkers in artificial and bioartificial liver support **2002**, 211-220

46 Tumour markers in gastrointestinal disease **2002**, 272-280

45 The impact of biochemical tests on patient management **2002**, 325-333

44 Monitoring liver transplant recipients **2002**, 423-432

43 The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers **2002**, 76-96

42 Genetic approaches to the study of complex diseases: osteoporosis **2002**, 159-164

41 IL-6-type cytokines and signalling in inflammation **2002**, 256-262

40 Serum markers of inflammation and cardiovascular risk **2002**, 345-354

39 An overview of S-100 β as a clinically useful biomarker of brain tissue damage **2002**, 406-412

38 Molecular diagnosis of cytomegalovirus disease **2002**, 467-473

37 Development of biomarkers: the industrial perspective **2002**, 16-23

36 Biomarkers in renal disease **2002**, 45-55

- 35 Biomarkers for evaluating the safety of genetically modified foods **2002**, 313-322
- 34 Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure **2002**, 334-344
- 33 Diagnosis and monitoring of inflammatory events in transplant recipients **2002**, 474-482
- 32 The clinical significance of markers of coagulation in acute coronary syndromes **2002**, 355-364
- 31 The clinical application of biomarkers in osteoporosis **2002**, 133-139
- 30 Toxicogenetic markers of liver dysfunction **2002**, 190-198 1
- 29 Endothelin: what does it tell us about myocardial and endothelial dysfunction? **2002**, 365-373
- 28 Biomarkers of neurodegenerative disorders **2002**, 391-397
- 27 Biomarkers of bone formation **2002**, 115-121
- 26 Homocysteine: a reversible risk factor for coronary heart disease **2002**, 374-378
- 25 Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy **2002**, 442-450
- 24 Early markers of nephrotoxicity for environmental and occupational monitoring **2002**, 66-75 1
- 23 The genetics of renal disease **2002**, 56-65
- 22 Prognostic markers in liver disease **2002**, 221-227
- 21 Apoptosis: biomarkers and the key role of mitochondria **2002**, 228-238
- 20 Monitoring heart and lung transplant patients **2002**, 415-422
- 19 Post-transplantation bone disease **2002**, 461-466
- 18 Using intelligent systems in clinical decision support **2002**, 32-42

17	Liver regeneration: mechanisms and markers 2002 , 239-243		
16	Protein profiling and proteomic databases 2002 , 299-312		
15	Matrix metalloproteinases and their tissue inhibitors 2002 , 379-388		
14	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. <i>Transplant Immunology</i> , 2002 , 9, 211-4	1.7	21
13	Cyclosporin monitoring based on C2 sampling. <i>Transplantation</i> , 2002 , 73, 840-1	1.8	9
12	Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. <i>European Journal of Heart Failure</i> , 2001 , 3, 155-63	12.3	23
11	Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 305-15	3.2	221
10	Proficiency testing schemes for therapeutics and toxicology. <i>Accreditation and Quality Assurance</i> , 2000 , 5, 389-391	0.7	
9	Delivering quality for the measurement of immunosuppressive drugs: current performance and future needs. <i>Accreditation and Quality Assurance</i> , 1999 , 4, 427-430	0.7	4
8	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. <i>Clinical Therapeutics</i> , 1999 , 21, 1632-52; discussion 1631	3.5	89
7	Therapeutic monitoring of mycophenolic acid. A consensus panel report. <i>Clinical Biochemistry</i> , 1998 , 31, 317-22	3.5	110
6	Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1410-6	1.6	31
5	Class III antiarrhythmics in overdose. Presenting features and management principles. <i>Drug Safety</i> , 1993 , 9, 450-62	5.1	15
4	Effects of amiodarone on the kinetics of antipyrine. <i>American Journal of Cardiology</i> , 1989 , 63, 991-2	3	2
3	Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments 1989 , 93-102		
2	Management of cardiac drug overdose. <i>Resuscitation</i> , 1984 , 11, 207-16	4	3
1	Amiodarone pharmacokinetics. <i>American Heart Journal</i> , 1983 , 106, 840-7	4.9	383